WINNIPEG, MANITOBA--(MARKET WIRE)--Jul 16, 2007 -- Miraculins Inc. (CDNX:MOM.V - News) (the “Company”), a biotechnology company dedicated to the discovery and validation of cancer biomarkers for use in developing diagnostic tools and therapeutic products, today announces a non-brokered private placement offering (the “Offering”) of up to 1,250,000 units (“Units”) at a price of $0.40 per Unit for gross proceeds of up to $500,000. Each Unit will be comprised of one common share of the Company (a “Share”) and one half of one Share purchase warrant (a “Warrant”). Each whole Warrant will entitle the holder to purchase one Share at a price of $0.65 per Share for a period of 12 months from the date the closing of the offering.
